MX2018001095A - Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico. - Google Patents

Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico.

Info

Publication number
MX2018001095A
MX2018001095A MX2018001095A MX2018001095A MX2018001095A MX 2018001095 A MX2018001095 A MX 2018001095A MX 2018001095 A MX2018001095 A MX 2018001095A MX 2018001095 A MX2018001095 A MX 2018001095A MX 2018001095 A MX2018001095 A MX 2018001095A
Authority
MX
Mexico
Prior art keywords
treatment
egfr
ductal adenocarcinoma
growth factor
monoclonal antibodies
Prior art date
Application number
MX2018001095A
Other languages
English (en)
Inventor
Siveke Jens
Steinmetz Tilman
De Dosso Sara
Schultheis Beate
E Iznaga Escobar Normando
Rohrberg Robert
Yalcin Suayib
Hofheinz Ralf
Overkamp Friedrich
Goker Erdem
M Behringer Dirk
Asiyah Ilyas Rikrik
Reuter Dirk
Kneba Michael
P Ebert Matthias
Dommach Markus
Schlegel Frank
E Schmidt Wolfgang
Strumberg Dirk
Bach Ferdinand
Kerkhoff Andrea
Original Assignee
Innocimab Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocimab Pte Ltd filed Critical Innocimab Pte Ltd
Publication of MX2018001095A publication Critical patent/MX2018001095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se refiere al campo de inmunoterapia de cáncer, en particular adenocarcinoma ductal pancreático (PDAC). Más específicamente, la presente invención proporciona medios y métodos para el tratamiento de una población de pacientes PDAC que sufren de tumores PDAC que expresan KRAS, HRAS o NRAS de tipo silvestre. Los medios y métodos de la invención prevén la administración de un anticuerpo anti-EGFR o fragmento de enlace a antígeno o péptido del mismo a los pacientes. Los medios y métodos para seleccionar pacientes y tumores para su respuesta al tratamiento también se proporcionan en la presente.
MX2018001095A 2015-07-27 2016-07-27 Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico. MX2018001095A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178489 2015-07-27
PCT/EP2016/067892 WO2017017133A1 (en) 2015-07-27 2016-07-27 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Publications (1)

Publication Number Publication Date
MX2018001095A true MX2018001095A (es) 2019-07-10

Family

ID=53776371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001095A MX2018001095A (es) 2015-07-27 2016-07-27 Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico.

Country Status (15)

Country Link
US (1) US20180221478A1 (es)
EP (1) EP3328426B8 (es)
KR (1) KR20180081482A (es)
CN (1) CN108348602A (es)
AU (1) AU2016299368B2 (es)
BR (1) BR112018001679A2 (es)
CA (1) CA2992375A1 (es)
DK (1) DK3328426T3 (es)
ES (1) ES2881385T3 (es)
MX (1) MX2018001095A (es)
MY (1) MY188446A (es)
PH (1) PH12018500003A1 (es)
RU (1) RU2728571C2 (es)
SG (1) SG10201912553QA (es)
WO (1) WO2017017133A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710054A4 (en) * 2017-11-18 2021-08-11 De Magalhaes, Nzola PRODUCT AND METHOD OF USING GC7 (N1-GUANYL-1,7-DIAMINOHEPTANE) BASED ANTIGEN BINDING CONJUGATES IN CANCER THERAPY
CU24558B1 (es) * 2017-11-28 2021-12-08 Ct Inmunologia Molecular Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
RU2712302C1 (ru) * 2019-07-24 2020-01-28 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ИМЕНИ АКАДЕМИКА А.М. ГРАНОВА" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ им. ак. А.М. Гранова" Минздрава России Способ лечения операбельной аденокарциномы двенадцатиперстной кишки
EP4450071A1 (en) * 2023-04-20 2024-10-23 Isofol Medical AB [6r]-mthf in b6 enhanced 5-fu based chemotherapy of pancreatic cancer
CN118221828A (zh) * 2023-09-08 2024-06-21 北京昌平实验室 Car分子、car细胞和car药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
EP0586002B1 (en) 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CU23612A1 (es) * 2006-09-29 2010-12-08 Centro Inmunologia Molecular Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
AU2013201584A1 (en) * 2012-03-12 2013-09-26 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody
GB201223025D0 (en) * 2012-12-20 2013-02-06 Medizinische Universitaet Graz Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients

Also Published As

Publication number Publication date
EP3328426B1 (en) 2021-04-07
ES2881385T3 (es) 2021-11-29
WO2017017133A1 (en) 2017-02-02
SG10201912553QA (en) 2020-02-27
US20180221478A1 (en) 2018-08-09
WO2017017133A8 (en) 2018-02-22
RU2017142804A3 (es) 2019-12-30
BR112018001679A2 (pt) 2018-09-18
AU2016299368A1 (en) 2018-02-22
AU2016299368B2 (en) 2022-03-10
PH12018500003A1 (en) 2018-07-09
RU2017142804A (ru) 2019-08-27
EP3328426A1 (en) 2018-06-06
KR20180081482A (ko) 2018-07-16
CN108348602A (zh) 2018-07-31
EP3328426B8 (en) 2021-06-02
MY188446A (en) 2021-12-09
DK3328426T3 (da) 2021-07-12
CA2992375A1 (en) 2017-02-02
RU2728571C2 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2018001095A (es) Tratamiento de pacientes diagnosticados con adenocarcinoma ductal pancreatico.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
NZ743881A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
NZ720353A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2015007846A (es) Anticuerpos anti-b7-h4 humana y sus usos.
PH12016501384B1 (en) Human antibodies to pd-l1
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
MX2016004286A (es) Biomarcadores de cancer y usos de los mismos.
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
TW201713360A (en) Methods of treating cancer using compositions of antibodies and carrier proteins
NZ631197A (en) Anti sez6 antibodies and methods of use
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
NZ601588A (en) Methods for treating breast cancer
CY1122156T1 (el) Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων
MX2021000439A (es) Anticuerpos de antigeno anti-tf humanizado.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021000783A (es) Anticuerpos humanizados contra psma.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
NZ709828A (en) Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX2021009514A (es) Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies